MedTrace Logo

An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea

NCT03352323 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2021-11-08

Study results available
· View outcomes & findings →

Summary

the study will measure the decrease in redness on the face of rosacea subjects

Conditions

  • Rosacea
  • Erythema

Interventions

DRUG

Oxymetazoline

RLD

Sponsors & Collaborators

  • Padagis LLC

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-18
Primary Completion
2017-12-06
Completion
2018-03-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03352323 on ClinicalTrials.gov